ReviewSensors (Basel, Switzerland)2013
Integration of biosensors and drug delivery technologies for early detection and chronic management of illness.
Review in Sensors (Basel, Switzerland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Biomolecules and Electrochemical Tools in Chronic Non-Communicable Disease Surveillance: A Systematic Review.Biosensors · 2020Pooled it
- Recent Advances in Micro- and Nano-Enhanced Intravascular Biosensors for Real-Time Monitoring, Early Disease Diagnosis, and Drug Therapy Monitoring.Sensors (Basel, Switzerland) · 2025Review
- Innovations in Biosensor Technologies for Healthcare Diagnostics and Therapeutic Drug Monitoring: Applications, Recent Progress, and Future Research Challenges.Sensors (Basel, Switzerland) · 2024Review
- Review
- Smart Contact Lenses as Wearable Ophthalmic Devices for Disease Monitoring and Health Management.Chemical reviews · 2023Review
- Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges.APL bioengineering · 2023Review
- Article
- Biosensor-Integrated Drug Delivery Systems as New Materials for Biomedical Applications.Biomolecules · 2022Review
- Flexible Sensing Systems for Cancer Diagnostics.Advances in experimental medicine and biology · 2022Article
- Distributed sensor and actuator networks for closed-loop bioelectronic medicine.Materials today (Kidlington, England) · 2021Article
- Conducting Silicone-Based Polymers and Their Application.Molecules (Basel, Switzerland) · 2021Review
- Review
- Soft, smart contact lenses with integrations of wireless circuits, glucose sensors, and displays.Science advances · 2018Article
- Graphene-Based Materials for Biosensors: A Review.Sensors (Basel, Switzerland) · 2017Review
- Review
- A Janus Mucoadhesive and Omniphobic Device for Gastrointestinal Retention.Advanced healthcare materials · 2016Article
- Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches.Sensors (Basel, Switzerland) · 2015Review
- Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment.Iranian journal of pediatric hematology and oncology · 2015Review
- Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors.Assay and drug development technologies · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in biosensor design and sensing efficacy need to be amalgamated with research in responsive drug delivery systems for building superior health or illness regimes and ensuring good patient compliance. A variety of illnesses require continuous monitoring in order to have efficient illness intervention. Physicochemical changes in the body can signify the occurrence of an illness before it manifests. Even with the usage of sensors that allow diagnosis and prognosis of the illness, medical intervention still has its downfalls. Late detection of illness can reduce the efficacy of therapeutics. Furthermore, the conventional modes of treatment can cause side-effects such as tissue damage (chemotherapy and rhabdomyolysis) and induce other forms of illness (hepatotoxicity). The use of drug delivery systems enables the lowering of side-effects with subsequent improvement in patient compliance. Chronic illnesses require continuous monitoring and medical intervention for efficient treatment to be achieved. Therefore, designing a responsive system that will reciprocate to the physicochemical changes may offer superior therapeutic activity. In this respect, integration of biosensors and drug delivery is a proficient approach and requires designing an implantable system that has a closed loop system. This offers regulation of the changes by means of releasing a therapeutic agent whenever illness biomarkers prevail. Proper selection of biomarkers is vital as this is key for diagnosis and a stimulation factor for responsive drug delivery. By detecting an illness before it manifests by means of biomarkers levels, therapeutic dosing would relate to the severity of such changes. In this review various biosensors and drug delivery systems are discussed in order to assess the challenges and future perspectives of integrating biosensors and drug delivery systems for detection and management of chronic illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.